Cargando…
Treating postmenopausal osteoporosis in women at increased risk of fracture – critical appraisal of bazedoxifene: a review
Several categories of drugs to treat osteoporosis exist in the form of bisphosphonates, strontium, parathyroid hormone, and selective estrogen receptor modulators (SERM). Advantages and disadvantages exist for each category as some patients may, for example, not tolerate bisphosphonates for gastroin...
Autores principales: | Vestergaard, Peter, Thomsen, Susanna vid Streym |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2971709/ https://www.ncbi.nlm.nih.gov/pubmed/21072279 |
Ejemplares similares
-
Bazedoxifene for the prevention of postmenopausal osteoporosis
por: Gennari, Luigi, et al.
Publicado: (2008) -
Efficacy and safety of bazedoxifene for postmenopausal osteoporosis
por: Kawate, Hisaya, et al.
Publicado: (2011) -
Incorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan
por: Ohta, H., et al.
Publicado: (2014) -
Efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: A systematic review and meta-analysis
por: Peng, Lihua, et al.
Publicado: (2017) -
Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture
por: Rossini, Maurizio, et al.
Publicado: (2013)